Efficacy and Safety of Butylphthalide for Acute Ischemic Stroke Patients Receiving Intravenous Thrombolysis or Endovascular Treatment

• Status: Recruiting
• Trial end date: 2022-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Butylphthalide, as a well-known neuroprotective medication, is a family of compounds initially isolated from the seeds of Apium graveolens Linn, of which active ingredient is dl-3-N-butylphthalide (dl-NBP). With the significant effects of reducing the cerebral ischemic damage and eventually improving patients' clinical outcomes, by the potential mechanisms of promoting microcirculation, as well as releasing oxidative stress, mitochondrial dysfunction and poststroke inflammation, dl-NBP has been widely applied in acute ischemic stroke as an anti-ischemic drug in China since 2002. While with the evolution of using iv. recombinant tissue plasminogen activator（rtPA ）and mechanical thrombectomy in acute ischemic stroke（AIS）patients, it is still undefined whether combination therapy with dl-NBP could enhance the curative effect. The primary purpose of this trial is to evaluate the recovery of neurological deficits in AIS patients who receive iv-rtPA and/or mechanical thrombectomy with the a 3-month regimen of Butylphthalide and Sodium Chloride Injection 100ml twice/day in the initial 14 days and Butylphthalide Soft Capsules 0.2g triple/day for the rest 15th to 90th day therapy versus a 3-month regimen of Butylphthalide Placebo Injection 100ml twice/day in the initial 14 days and followed by Butylphthalide Placebo Soft Capsules 0.2g triple/day for the rest 15th to 90th day therapy.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Beijing Tiantan Hospital; Ministry of Science and Technology of the People´s Republic of China
• Treatments: 3-n-butylphthalide

Criteria

Inclusion Criteria:

1. Female or male aged ≥ 18 years.

2. Acute ischemic stroke.

3. Within 6 hours from symptom onset.

4. Baseline NIHSS range 4 from 25.

5. Proceed to iv-rtPA or intravascular therapy including arterial thrombolysis and mechanical thrombectomy or bridging therapy.

6. Provision of informed consent.

Exclusion Criteria:

1. Modified Rankin Scale（mRS）>1 at randomization (pre-morbid historical assessment).

2. ASPECT ≤ 6 confirmed by the pre-operation CT scan.

3. Diagnosis of intracranial hemorrhagic disease, such as intracranial hemorrhage, subarachnoid hemorrhage and so on.

4. Use any drugs related to Butylphthalide during onset between randomization.

5. Dysphagia at the onset of stroke.

6. History of coagulation dysfunction, systemic bleeding, neutropenia or thrombocytopenia.

7. History of chronic hepatopathy, liver and kidney dysfunction, elevating Alanine transaminase (> 3 times normal upper limit), elevating serum creatinine (> 2 times normal upper limit).

8. History of severe cardio-pulmonary diseases which is not suitable for this study judged by investigator.

9. History of bradycardia (heart rate < 60 beats/m) and Sick sinus syndrome.

10. Severe non-cardiovascular comorbidity with life expectancy < 3 months or failed to follow the study for other reasons.

11. History of drug or food allergy, or are known to be allergic to the drug components of this study.

12. Contraindications for the digital subtraction angiography procedure, including severe allergy for contrast agent with or without Iodine.

13. Pregnancy or lactation, and women of childbearing age not practicing reliable contraception who do not have a documented negative pregnancy test.

14. Incapable to follow this study for mental illness, cognitive or emotional disorder.

15. Unsuitable for this study in the opinion of the investigators.